SpotitEarly Partners with HITLAB to Accelerate U.S. Launch of Non-Invasive Cancer Screening

---

SpotitEarly, a multi-cancer early-detection company, announced a strategic partnership with HITLAB on Thursday to accelerate the commercialization of its non-invasive cancer screening test across the United States. The collaboration aims to leverage HITLAB's extensive network and expertise to support SpotitEarly’s growth through investor introductions, strategic advisory services, and speaking opportunities.

Key Features of the Partnership

• Investor Introductions: HITLAB will facilitate connections with potential investors to secure funding for further development and market expansion.
• Strategic Advisory: The partnership includes ongoing guidance on regulatory compliance, clinical trial design, and market entry strategies.
• Speaking Opportunities: SpotitEarly will gain access to key industry events and platforms to showcase its technology and build credibility in the healthcare community.

SpotitEarly plans to launch its breast cancer breath test commercially by 2027. The LUCID Bio-AI Hybrid system at the core of this innovation combines machine learning with the scent-detection abilities of trained canines. This unique approach captures and standardizes the dogs' behavioral and physiological responses, transforming them into consistent, data-driven results.

Under the Hood

The LUCID Bio-AI Hybrid system works by analyzing volatile organic compounds (VOCs) in a person's breath. These VOCs are biomarkers that can indicate the presence of cancer at an early stage. Here’s a breakdown of how it functions:

• Data Collection: Breath samples are collected using specialized sensors.
• Canine Detection: Trained dogs sniff the samples and their reactions are recorded.
• AI Integration: Machine learning algorithms analyze the data from both the sensors and canine responses to identify patterns associated with cancer.

Shlomi Madar, Ph.D., CEO of SpotitEarly, emphasized the significance of this partnership: "We’ve built the clinical evidence and the partnerships with world-class institutions. The next step is making sure the investment and healthcare communities see what our data shows and understand the scale of the opportunity. HITLAB sits at the center of digital health innovation and connects us directly with the investors, health-system leaders, and key opinion leaders who can help bring this technology to the patients who need it."

What to Watch

• Regulatory Approval: SpotitEarly will need to navigate the FDA approval process, which can be complex and time-consuming.
• Market Adoption: Success in the market will depend on healthcare providers' willingness to adopt new technologies and integrate them into their practices.
• Competitive Landscape: Other companies are also developing early cancer detection methods, so SpotitEarly will need to differentiate itself through clinical evidence and robust partnerships.

The partnership with HITLAB is a significant step forward for SpotitEarly, positioning it well to bring its innovative breath test to the U.S. Market and potentially revolutionize cancer screening practices.